The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Emicizumab for severe von Willebrand disease: the EmiVWD study
In this interview, Jonathan Roberts, MD, The Bleeding & Clotting Disorders Institute, Peoria, IL, introduces the EmiVWD trial (NCT05500807), a pilot, multicenter, prospective, open-label study evaluating emicizumab prophylaxis in severe von Willebrand disease (VWD). The trial also allows for enrollment of patients with concomitant hemophilia A and VWD. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
